{"name":"Biotest","slug":"biotest","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"BT063","genericName":"BT063","slug":"bt063","indication":"Other","status":"phase_2"},{"name":"BT595","genericName":"BT595","slug":"bt595","indication":"Severe bleeding or hemostatic support in patients with bleeding disorders","status":"phase_3"},{"name":"Placebo (human albumin 1%)","genericName":"Placebo (human albumin 1%)","slug":"placebo-human-albumin-1","indication":"Placebo control in Phase 3 clinical trial (specific indication unknown)","status":"phase_3"},{"name":"Trimodulin","genericName":"Trimodulin","slug":"trimodulin","indication":"Other","status":"phase_3"},{"name":"Zutectra","genericName":"Zutectra","slug":"zutectra","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BT061","genericName":"BT061","slug":"bt061","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_2"},{"name":"BT086","genericName":"BT086","slug":"bt086","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_2"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"BT524","genericName":"BT524","slug":"bt524","indication":"Rare bleeding disorders associated with TFPI dysregulation","status":"phase_3"},{"name":"BT524 (Part I)","genericName":"BT524 (Part I)","slug":"bt524-part-i","indication":"Rare bleeding disorders associated with TFPI dysregulation","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"BT524 (Part II)","genericName":"BT524 (Part II)","slug":"bt524-part-ii","indication":"Severe bleeding or hemostatic support in patients with coagulopathies","status":"phase_3"},{"name":"FFP/Cryo","genericName":"FFP/Cryo","slug":"ffp-cryo","indication":"Severe bleeding with coagulopathy","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Civacir® 10%","genericName":"Civacir® 10%","slug":"civacir-10","indication":"Prevention of hepatitis C virus reinfection in HCV-positive patients undergoing orthotopic liver transplantation","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"IgG Next Generation (BT595)","genericName":"IgG Next Generation (BT595)","slug":"igg-next-generation-bt595","indication":"Primary immunodeficiency disorders","status":"phase_3"}]}],"pipeline":[{"name":"BT061","genericName":"BT061","slug":"bt061","phase":"phase_2","mechanism":"BT061 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"BT063","genericName":"BT063","slug":"bt063","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BT086","genericName":"BT086","slug":"bt086","phase":"phase_2","mechanism":"BT086 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"BT524","genericName":"BT524","slug":"bt524","phase":"phase_3","mechanism":"BT524 is a human monoclonal antibody that binds to and neutralizes tissue factor pathway inhibitor (TFPI) to enhance thrombin generation and hemostasis.","indications":["Rare bleeding disorders associated with TFPI dysregulation","Hemophilia or other coagulation deficiencies (investigational)"],"catalyst":""},{"name":"BT524 (Part I)","genericName":"BT524 (Part I)","slug":"bt524-part-i","phase":"phase_3","mechanism":"BT524 is a human monoclonal antibody that binds to and neutralizes tissue factor pathway inhibitor (TFPI) to enhance thrombin generation and hemostasis.","indications":["Rare bleeding disorders associated with TFPI dysregulation","Hemophilia or other coagulation factor deficiencies (investigational)"],"catalyst":""},{"name":"BT524 (Part II)","genericName":"BT524 (Part II)","slug":"bt524-part-ii","phase":"phase_3","mechanism":"BT524 is a human monoclonal antibody that binds to and neutralizes tissue factor pathway inhibitor (TFPI) to enhance thrombin generation and hemostasis.","indications":["Severe bleeding or hemostatic support in patients with coagulopathies"],"catalyst":""},{"name":"BT595","genericName":"BT595","slug":"bt595","phase":"phase_3","mechanism":"BT595 is a human monoclonal antibody that binds to and neutralizes tissue factor pathway inhibitor (TFPI) to enhance thrombin generation and hemostasis.","indications":["Severe bleeding or hemostatic support in patients with bleeding disorders"],"catalyst":""},{"name":"Civacir® 10%","genericName":"Civacir® 10%","slug":"civacir-10","phase":"phase_3","mechanism":"Civacir is a hepatitis C immunoglobulin (HCV-IG) that provides passive immunity by supplying antibodies against hepatitis C virus to prevent reinfection in transplant recipients.","indications":["Prevention of hepatitis C virus reinfection in HCV-positive patients undergoing orthotopic liver transplantation"],"catalyst":""},{"name":"FFP/Cryo","genericName":"FFP/Cryo","slug":"ffp-cryo","phase":"phase_3","mechanism":"FFP/Cryo is a combination blood product therapy that replaces clotting factors and fibrinogen to restore hemostatic function in patients with severe bleeding or coagulopathy.","indications":["Severe bleeding with coagulopathy","Massive transfusion protocol","Disseminated intravascular coagulation (DIC)","Fibrinogen deficiency or dysfunction"],"catalyst":""},{"name":"IgG Next Generation (BT595)","genericName":"IgG Next Generation (BT595)","slug":"igg-next-generation-bt595","phase":"phase_3","mechanism":"BT595 is a next-generation intravenous immunoglobulin (IVIG) product designed to provide passive immunity through polyclonal IgG antibodies with enhanced manufacturing and purification processes.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions (specific indications in Phase 3 trials not publicly detailed)"],"catalyst":""},{"name":"Placebo (human albumin 1%)","genericName":"Placebo (human albumin 1%)","slug":"placebo-human-albumin-1","phase":"phase_3","mechanism":"Human albumin 1% serves as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.","indications":["Placebo control in Phase 3 clinical trial (specific indication unknown)"],"catalyst":""},{"name":"Trimodulin","genericName":"Trimodulin","slug":"trimodulin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zutectra","genericName":"Zutectra","slug":"zutectra","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPZkxHTGhRM3BrQTJUU3lCRW9jaDFHaF9ONVVXSzlnM1VyT0ZtbUgzdGdkTnFvcVljVl8zZU5tV3Y2MlNqTlF6Qkw5TldaREZJRzBBLTRUTU80M1g2M1FnWktnU3lkQktYcFpvWFN2RGs3RlU5Tld0UTYxNzFtSEZwam15cDIwZUdGNFZkYlFnSQ?oc=5","date":"2025-11-27","type":"pipeline","source":"The Pharma Letter","summary":"Grifols appoints Tomás Dagá as VP Egypt JV - The Pharma Letter","headline":"Grifols appoints Tomás Dagá as VP Egypt JV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNQ2V0ZzdNQ19Ld3hCTTVnVzhwVVZKN1VTSGo4MlFhVklTTExCWlduOTZTNXZuTkFxNnEzLWlONkM0T3R3X3FCUHhxcU5zaFpJTkFYN2NwYnp0Z2hLRTVTYVBoWHFYZjNiODdLbWdGSHRrb1pRM0RjQjdZdUpQYk9IbmY2d2RNeS1HeWFpUjc5cjd5S3VWSFZFUFI2MXpDN2NfZmVEVmNIU1FuSHZEU3NjTm1uMWt6clc5dEloaDVn?oc=5","date":"2025-11-13","type":"regulatory","source":"The Pharma Letter","summary":"Grifols’ Biotest wins first regulatory approval for its fibrinogen concentrate - The Pharma Letter","headline":"Grifols’ Biotest wins first regulatory approval for its fibrinogen concentrate","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOcHdSQU1GV2pGYWRRd3JVMWY3YUluMUJaaWRTTkQ3YzRZMktZT0NIRmoyLWNWOHpEVmVoc2tmMVk0NGt1Zk9uUVpEckl6VFNBLTZLaUNnTDMzNTV0cExYQXZNV1JpdGx6OHEtbWROcE9XS2d6bW92alJTTmZabDRlUGJfazVPNXVVWk9Ea1Q2a3U0VE92SlhaUk1kTU9Lb3RkMFJQeWFNMnJCLWQ4bXhra24tS193OFRnY1E?oc=5","date":"2025-06-16","type":"pipeline","source":"Osborne Clarke","summary":"Osborne Clarke advises Grifols on delisting offer and delisting from stock exchange of Biotest - Osborne Clarke","headline":"Osborne Clarke advises Grifols on delisting offer and delisting from stock exchange of Biotest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBzZWJuNTcxUGJhSlhmNnJMal8zVEdqRUtyNllLcktrdUJYMWxOc1ZMdzJNTTJDcW5XMkVUYkwtU2hzaU5LODlrUUtkYmJkZ0ZFaEJHbnUycVhMSVVsRVBvWmZucG5NLUlvaXcyMVNZZHp6LUk1ODQzZnpYNW5PUXc?oc=5","date":"2025-01-09","type":"pipeline","source":"pharmaphorum","summary":"Grifols files drug for rare bleeding disorder in the US - pharmaphorum","headline":"Grifols files drug for rare bleeding disorder in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPR2MyLXg2THJSSU84SUV4SVkyNHlpSFJWdmJCbjhoaG16UDc3S3BuU2JMS2ZMQ3V5NUxwOXpFSFg5X0ZCZ1R5VEQyQTljc2hqb0c1Vi1LUlY2aEJzS2tEdWdPUVgyT1ZwaFdvaWY1SENJZzhtY1VLN1o0clRVbHZkQlI3bm0zdl8xYjBZdzRhakppSkNNcURXMjVSY1hmSFdLMS1sTUVEVVRtLW1DVWVNX3VZNDFldnVoQ1VjaGV5bk5jaFd1SERxQkhkbVJnalBvOXBJdVNQYjJMNGFTaWZSMlVnQQ?oc=5","date":"2024-10-02","type":"pipeline","source":"PR Newswire","summary":"Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US - PR Newswire","headline":"Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNNXc1TFI3b1J2alVnXzBlOWpiY3o4c1prWHlHY0dleV9VaWlud1hPakNlbENNSlFHckxic2pjcHlsaXJCbFUzNUtLUGQzd25kYkhDWmszODExMzdXUThvNjlWUXNmRm1RenJ0RFI5TEZhTHNScUl0SnpsNGJHdFdIbWsxNk43S3Z2TGZaeGVEclVEVnVNUUpQZzZmZmV2REdWT01pVnN3?oc=5","date":"2024-06-18","type":"regulatory","source":"PharmTech.com","summary":"FDA Approves Immunoglobulin Therapeutic to Treat Primary Immunodeficiencies - PharmTech.com","headline":"FDA Approves Immunoglobulin Therapeutic to Treat Primary Immunodeficiencies","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQR0VTekRDOV82alZsNUIyajRsTEpNNU1CTXk1UU1iZFZ1cXBsMWJSUUduOG1XX1M3WURPMHJZWmRzWTJuVmUxenRrVDAwbHlBX0VxZWFYZ08zdDlYMGdSc1hKRV9jUDV4Nkg3TFJKbWJBVlhNa3VlSzlUUjR3b1A3aVluc1o4RXpRN21FZkFkTm9OOFE3cHkyX3d4NlZ2S2MwYXc?oc=5","date":"2024-06-17","type":"regulatory","source":"Pharmaceutical Technology","summary":"Biotest wins FDA approval for plasma protein therapy - Pharmaceutical Technology","headline":"Biotest wins FDA approval for plasma protein therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNZHNjdkJLQ1FuOUNHeVpWa21ISVRQQm5uMUhZcHVsVDFzVmRUeWg1ZmVzTnBoeDR6NGhsSnh0dTcydTRQVnk4OXVfY1pTeGRlRmdpejRNNFZ4N3VKNUJQWFdfMXRTRmR6NHQzWGxRbTQwbDdlZTdtYmhZNUZYcFhaYjdQamszcmZFMVhnT2tCcWZqYVJPTDRlSTR0YlBsdw?oc=5","date":"2024-03-02","type":"pipeline","source":"BioProcess International","summary":"Establishing Single-Use Assemblies on Filling Equipment - BioProcess International","headline":"Establishing Single-Use Assemblies on Filling Equipment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9TaWplQXl5bDlyNWsza1JHR2J2aXhGSkhaaGJIUktGMWl1enRoRk9OZ3ZtM2ptZ1FrRVBtVG1wejZyeVBFZGZRUXhnVDNTZ0syWVJRLWtlVWliVGtmeUJvSEtfcEFlNjFJWkREcTZ1bw?oc=5","date":"2023-10-05","type":"pipeline","source":"PharmaTimes","summary":"Jörg Schüttrumpf - PharmaTimes","headline":"Jörg Schüttrumpf","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxObVZxLW5paXQ0Z25hcTdxQWZiZWRKZ1lFakViMzJlSXBTbkhrZ1VFTEZ3aC15NmNacG1NdktUa2Z5dllFVndzbkRpSHZnSHk5NEMyalFXV0tzWTVSRDJsbm54VWcwVldkMnRiTXBCTXdQNXoweThhYWpYODFlLXkyQWo3dHFuUlp6MUphd2VKaV9xWlRSdV9zSnFrTXFBbGZ0RWtvTGtvWjFyRGFWZFlNVy1zbzNYcm5ydW1J?oc=5","date":"2019-05-13","type":"pipeline","source":"Fierce Pharma","summary":"ADMA Biologics returning Bivigam to market after 3-year absence - Fierce Pharma","headline":"ADMA Biologics returning Bivigam to market after 3-year absence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNRlBfVWRIZlF0akxxaUZ4cFUzeFJ1VTVFWlQyUnNBY1c3Y0t5VVZBUHB3akdSaWk1R0JpQXlhbWJtb2EwbmE2dWRyZndwWEJXdDJEdFdTU2hOWWZHTzlWVjNaQzQzMGJ4TXZXNFF3bHdqWUlDRGZETFc5M0QyT2hTVzRXZl9lb2stZHNqOWdvRDAyVTZBNFFCbA?oc=5","date":"2018-08-02","type":"pipeline","source":"BioPharma Dive","summary":"Success for ADMA as Bivigam inspection file closes - BioPharma Dive","headline":"Success for ADMA as Bivigam inspection file closes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOUDY0TjBEQm1aejFKVVI0a1RhNU5hR1E1OGdxaFJCV3RSWVFNTjBteHN2alduLThFZUEzMjFxX0pPQ0o2RTJCS1A2VDZTR3Z1ZUZtLVZuWWRaWXBaODVTcFRPQ3U3bFZXTUVHbzNSOG5aQ1ZwQUJCb3V4MmRlT21XYldiQU5RaTdablJIT0dIdWRuVGtUNW81TzFBcF9kcFpTajNOVi16dWZDbTY2Rmd2Mg?oc=5","date":"2017-01-23","type":"deal","source":"New Jersey Business Magazine","summary":"ADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation - New Jersey Business Magazine","headline":"ADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_2":3,"phase_3":10},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}